Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.62 |
| ▸ | MMP3 | P08254 | 12/20 | 0.62 |
| ▸ | MMP1 | P03956 | 10/20 | 0.62 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.61 |
| ▸ | MMP7 | P09237 | 6/20 | 0.59 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | CPA1 | P15085 | 1/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055025 | 0.91 | MMP2 (0.77) | MMP2MMP3MMP1MMP7 | |
| SCHEMBL8469705 | 0.88 | MMP2 (0.50) | MMP2MMP3MMP1BIRC2MMP7 | |
| SCHEMBL8468208 | 0.85 | BIRC2 (0.46) | MMP2MMP3MMP1BIRC2MMP7 | |
| SCHEMBL8828135 | 0.83 | MMP3 (0.72) | MMP2MMP3MMP1MMP7 | |
| SCHEMBL29232996 | 0.82 | MME (0.67) | MMP2MMP3MMP1BIRC2MMP7 | |
| SCHEMBL4289464 | 0.82 | ACE (0.54) | MMP2MMP7MMEACECPA1 | |
| SCHEMBL4289468 | 0.82 | ACE (0.54) | MMP2MMP7MMEACECPA1 | |
| SCHEMBL8828145 | 0.82 | MMP2 (0.61) | MMP2MMP3MMP1MMP7 | |
| SCHEMBL8828128 | 0.81 | MMP1 (0.72) | MMP2MMP3MMP1MMP7 | |
| SCHEMBL8828106 | 0.81 | MMP1 (0.75) | MMP2MMP3MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-29 | — | — | US | claimed |
| US-6660741-B2 | Coupling an O-protected methoxypyrrolidine or derivatives with N-protected amino acid 2,5-dioxo-pyrrolidinyl ester to form intermediate, deportecting with trifluoroacetic acid to form pyrrolidine-1-carbonyl-2-methylamine or derivatives | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-09 | — | — | US | claimed |
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2002-12-26 | — | — | US | claimed |
| US-20050272667-A1 | Analogs and derivatives of (S,S,R)-(-)-actinonin and uses therefor | SCHEINBERG DAVID | 2005-12-08 | — | — | US | disclosed |
| US-6887887-B2 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-29 | — | — | US | disclosed |
| US-6660741-B2 | Coupling an O-protected methoxypyrrolidine or derivatives with N-protected amino acid 2,5-dioxo-pyrrolidinyl ester to form intermediate, deportecting with trifluoroacetic acid to form pyrrolidine-1-carbonyl-2-methylamine or derivatives | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-09 | — | — | US | disclosed |
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | HASPIN, CYTH2, ACTR3 | MMP2 2210/4885MMP3 2111/4885MMP1 3205/4885 |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | HASPIN, CYTH2, CYTH3 | MMP2 2144/4885MMP3 2147/4885MMP1 3199/4885 |
| US-20050272667-A1 | Analogs and derivatives of (S,S,R)-(-)-actinonin and uses therefor | CYTH3, ACTR3, HASPIN | MMP2 1607/4885MMP3 1631/4885MMP1 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.